Abstract Cyclooxygenase-2 (COX-2) inhibition prevents adenoma formation in humans and
mouse models of colon cancer. The selective COX-2 inhibitor celecoxib reduces COX-2 and …

Anti-inflammatory drugs prevent intestinal tumor formation, an activity related to their ability
to inhibit inflammatory pathway signaling in the target tissue. We previously showed that …

Nonsteroidal anti-inflammatory drugs decrease sporadic colorectal carcinoma and
adenomas in patients with familial adenomatous polyposis and in rodent models of sporadic …

COX-2 has been inappropriately overexpressed in various human malignancies, and is
considered as one of the representative targets for the chemoprevention of inflammation …

Genetic deletion or pharmacological inhibition of cyclooxygenase (COX)-2 abrogates
intestinal adenoma development at early stages of colorectal carcinogenesis. COX-2 is …

Growing evidence shows that Interleukin (IL)-1β and Cyclooxygenase 2 (COX-2) play a
crucial role in the pathogenesis of inflammatory diseases and tumor growth, particularly in …

Accumulating evidence has indicated that inflammatory responses are important for cancer
development. Epidemiological studies have shown that regular use of non-steroidal anti …

Colorectal cancer (CRC) is a heterogeneous disease, including at least three major forms:
hereditary, sporadic and colitis-associated CRC. A large body of evidence indicates that …

Patients with inflammatory bowel diseases are at increased risk for colorectal cancer.
Pharmacological inhibition of cyclooxygenase (COX) function exacerbates symptoms in …

Clinical and animal studies indicate a role for cyclooxygenase-2 (COX-2) and the epidermal
growth factor receptor (EGFR) in the development and progression of intestinal polyps and …